Related Experiment Videos
[Serotype 5 pneumococcus in epidemiology and vaccine]
Bulletin Europeen De Physiopathologie Respiratoire
|March 1, 1983
Summary
Streptococcus pneumoniae serotype 5 is immunogenic and well-tolerated, whether given alone or with a 14-valent pneumococcal vaccine. This finding supports its inclusion in future pneumococcal vaccines.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Streptococcus pneumoniae serotype 5 is a significant pathogen in human infections, particularly pneumonia and meningitis.
- It is prevalent in Africa and ranks among the top pneumococcal serotypes in France.
Purpose of the Study:
- To evaluate the immunogenicity and tolerance of Streptococcus pneumoniae serotype 5 polysaccharide.
- To assess the potential interference when combined with a 14-valent pneumococcal vaccine.
Main Methods:
- Four adult groups were immunized: serotype 5 alone, a 15-valent vaccine (14-valent + serotype 5), or a 14-valent vaccine.
- Antibody levels were measured using radioimmunoassay (RIA) to determine geometric mean multiplying factors.
Main Results:
- Serotype 5 polysaccharide demonstrated immunogenicity when administered alone or in combination with the 14-valent vaccine.
- No interference was observed between serotype 5 and the other 14 pneumococcal polysaccharides.
- The tolerance of serotype 5 polysaccharide was comparable to the 14 antigens in the vaccine.
Conclusions:
- Streptococcus pneumoniae serotype 5 polysaccharide is immunogenic and safe for use in adults.
- Its incorporation into the 14-valent pneumococcal vaccine is feasible without compromising immune response or safety.